I-Mab
(NASDAQ : IMAB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. 0.85%93.831.9%$1163.93m
BMYBristol-Myers Squibb Co. 0.71%61.321.0%$1017.19m
JNJJohnson & Johnson 0.37%147.270.7%$1009.80m
PFEPfizer Inc. -0.22%35.930.9%$970.99m
MRKMerck & Co., Inc. 0.82%82.220.7%$859.42m
LLYEli Lilly & Co. -1.02%149.171.1%$531.64m
AZNAstraZeneca Plc -0.04%53.851.2%$283.65m
NVSNovartis AG 0.93%85.910.2%$152.29m
GSKGlaxoSmithKline Plc 0.11%41.700.2%$126.54m
NVONovo Nordisk A/S 0.23%64.490.1%$83.99m
SNYSanofi 0.30%50.100.2%$78.95m
RGENRepligen Corp. -1.28%120.267.1%$68.99m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 1.08%68.140.0%$52.90m
RETAReata Pharmaceuticals, Inc. -2.49%126.303.4%$37.91m
TPTXTurning Point Therapeutics, Inc. 1.28%62.980.0%$37.82m

Company Profile

I-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China.